Floatz logo

TAURURSODIOL

Amyotrophic Lateral Sclerosis

Amylyx Pharmaceuticals Inc.Small moleculePhase 3Active
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
74/ 100
Competitive Position
73/ 100

Competitive context

150 Active assets in the Amyotrophic Lateral Sclerosis cohort.

Asset / SponsorPhaseRating
Tofersen
Biogen
Phase 4BBB
Riluzole
AB Science
Phase 4BB
Mexiletine
Bjorn Oskarsson, MD
Phase 4BB
DIACETYL(N(4)-METHYLTHIOSEMICARBAZONATO) COPPER (II)
Collaborative Medicinal Development Pty Limited
Phase 2/3BB
mt-1186
Tanabe Pharma Corporation
Phase 3BB

View all 50 →

Same molecule, other indications

TAURURSODIOL is also rated in:

primary biliary cholangitisDormant
BB
Indicative ·
64 / 100
View asset →
wild type ATTR amyloidosisDormant
BB
Indicative ·
64 / 100
View asset →
Transthyretin AmyloidosisDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →